Collegium Pharmaceutical, Inc. (COLL) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-02-26
Business type: Franchise
How it makes money
It earns revenue by selling prescription pain and ADHD medications, relying on physicians choosing its branded formulations over generic alternatives.
It derives profit from the sale of controlled substances, specifically opioids for pain management and stimulants for ADHD treatment. The primary driver of profitability is the successful commercialization of these brands within the U.S. market, which depends on physician prescription behavior, patient acceptance, and the reimbursement policies set by healthcare payors.
What protects it: the moat
It maintains market position through FDA-granted periods of exclusivity, specialized formulation technologies, and established authorized generic distribution agreements.
The company relies on regulatory exclusivity, such as pediatric patient population status, to delay generic entry for its products. Additionally, it utilizes proprietary delivery platforms like DETERx to create abuse-deterrent formulations, which it argues differentiates its products from standard alternatives. Management also claims competitive defense through established sales and marketing capabilities.
What growth costs
It reinvests capital into business acquisitions and mandatory safety oversight programs to maintain its portfolio of controlled substances.
Growth is largely driven by the acquisition of established product portfolios, such as the purchase of Ironshore and BDSI. Ongoing operational expenses include mandatory Risk Evaluation and Mitigation Strategy programs, which are legal requirements for selling its opioid products. The company does not specify R&D or capital expenditure figures in the provided text.
What could damage it
Regulatory or social shifts regarding opioid usage could permanently impair its ability to market its core pain management portfolio.
The company's reliance on opioid products exposes it to the risk that changing law enforcement priorities, regulatory crackdowns, or public perception regarding addiction could shrink its addressable market or lead to more stringent, cost-prohibitive marketing restrictions.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.